---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-24-000195"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:25.386419+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement

## Summary
- Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
- Cash & equivalents $13.1M, no debt as of Sep 30, 2024.
- $230,700 product revenue from Cartessa Aesthetics supply agreement in Q3.
- Blinded Phase 2 data: 70% of 10 patients at 26 wks had >30% pain reduction, >30% function increase.
- No SAEs or dose-limiting toxicity at 26–52 wks; provisional NYSDOH license for allogeneic processing.

## SEC filing metadata
- accession: 0001021771-24-000195
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000195/0001021771-24-000195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000195/brt8k111224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-24-000195
- JSON: https://secwatch.observer/filing/0001021771-24-000195.json
- Plain text: https://secwatch.observer/filing/0001021771-24-000195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.